What Happened?
, -based Immunovant Appointed Shari Duralek as Director Global Clincial Supply Chain
About the Company
Immunovant is a biopharmaceutical company committed to developing innovative therapies that not only treat the symptoms, but modify the course of autoimmune diseases. Our primary investigational product candidate is RVT-1401, a human recombinant anti-FcRn monoclonal antibody that is being developed with a focus on patient need, and may be applicable to a wide array of autoimmune diseases. We are currently assessing RVT-1401 in a single and multiple ascending dose Phase 1 clinical trial. We plan on initiating a number of patient-based studies in early 2019, focusing on Myasthenia gravis (MG) and other IgG-mediated diseases. We also seek to continue expanding our pipeline, ultimately transforming the lives of patients with autoimmune diseases.
About the Person
Shari Duralek is Director Global Clincial Supply Chain at Immunovant. Previously, Shari held various senior HR leadership roles in the industry.
Info Source
News
Short Profile